The Federal Trade Commission on Jan. 14 published a second interim staff report on the prescription drug middleman industry, ...

According to the survey cited by NCPA, 60.4% of independent pharmacists are considering not stocking one or more of the first ...

The villains were injectable specialty drugs like Keytruda and inpatient surgical procedures for seriously ill patients.

Bloomfield-based Cigna announced this week a new initiative that aims to reduce out-of-pocket prescription-drug costs and ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

Iowa lawmakers introduce bills to stop Pharmacy Benefit Managers from giving pharmacies less money than it costs to fill prescriptions.

GRAND JUNCTION, Colo. (KJCT) -A bipartisan bill was introduced into the house this week regarding healthcare costs for Coloradans. The bill introduced by Representatives Kyle Brown and Dusty Johnson ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

Cigna executives kicked off Thursday’s earnings call by responding to pharmacy benefit manager critics with a number of reforms.

At the Senate Finance nomination hearing yesterday, he declined to give a yes-or-no answer about Affordable Care Act tax credit rule renewal.

According to Bloomberg, a top Cigna executive said it will prevent patients from paying the full list price for drugs, or more than their employer has contributed.